Anti-AHA1 Antibody

(No reviews yet) Write a Review
SKU:
STPA00032
Antibody Type:
Polyclonal
Applications:
WB
Applications:
IHC
Applications:
ICC/IF
Applications:
IP
Applications:
ELISA
Reactivity:
Human
Reactivity:
Mouse
Reactivity:
Rat
Host Species:
Rabbit
  • Immunocytochemistry/Immunofluorescence analysis using Rabbit Anti-AHA1 Polyclonal Antibody (STPA00032). Tissue: Heat Shocked Cervical cancer cell line (HeLa). Species: Human. Fixation: 2% Formaldehyde for 20 min at RT. Primary Antibody: Rabbit Anti-AHA1 Polyclonal Antibody (STPA00032) at 1:60 for 12 hours at 4°C. Secondary Antibody: R-PE Goat Anti-Rabbit (yellow) at 1:200 for 2 hours at RT.
  • Western blot analysis of multiple Cell line lysates showing detection of AHA1 protein using Rabbit Anti-AHA1 Polyclonal Antibody (STPA00032). Load: 15 µgprotein. Block: 1.5% BSA for 30 minutes at RT. Primary Antibody: Rabbit Anti-AHA1 Polyclonal Antibody (STPA00032) at 1:1000 for 2 hours at RT. Secondary Antibody: Donkey Anti-Rabbit IgG: HRP for 1 hour at RT.
Frequently bought together:

Description

AHA1 Antibody

AHA1 Antibody is a rabbit polyclonal antibody directed against AHA1, offered by Assay Genie for research applications. Reported applications include WB, IHC, ICC/IF, IP and ELISA. Reported reactivity: Human, Mouse and Rat. Purified by Protein A.

Activator of HSP90 ATPase Homolog 1 (AHA1) is a critical member of the HSP90 co-chaperone family, known for its role in regulating protein folding and stability. AHA1 enhances the ATPase activity of HSP90, a central molecular chaperone, by competitively displacing other co-chaperones such as p23, thereby accelerating the chaperone cycle and influencing client protein maturation. AHA1 is implicated in endoplasmic reticulum (ER) to Golgi trafficking, a process essential for proper protein sorting and cellular homeostasis. It also interacts with HSP90 (HSPCA) and the cytoplasmic tail of vesicular stomatitis virus glycoproteins (VSV G), suggesting a broader role in viral pathogenesis and intracellular transport mechanisms. Importantly, AHA1 is widely expressed across multiple tissues, including the brain, heart, skeletal muscle, and kidney, with lower expression levels observed in the liver and placenta. Its presence in the central nervous system highlights its potential relevance in neurodegenerative disease pathways, where protein misfolding and aggregation are hallmark features. Emerging evidence suggests that targeting AHA1 may enhance the efficacy of HSP90 inhibitors, positioning it as a promising therapeutic co-target in diseases characterized by proteostasis imbalance, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 100 µl. For research use only; not for diagnostic or therapeutic procedures.

View AllClose

0 Reviews

View AllClose